CAJ | 학술논문

目的探讨低分子肝素钙联合川穹嗪、糖皮质激素治疗慢性阻塞性肺疾病(COPD)的可行性及安全性.方法把2008~2011年收治的200例慢性阻塞性肺疾病患者随机分为两组.对照组:采用低流量持续吸氧、抗感染、化痰及体位引流排痰、扩张支气管等对症处理.观察组:在对照组治疗的基础上加用低分子肝素钙、川穹嗪、糖皮质激素治疗.结果一周后,观察组患者的咳痰喘症状,右心功能不全,生活质量好转率好于对照组;血气分析检查:观察组患者的动脉血氧分压、血氧饱和度改善率好于对照组;6min 步行试验:观察组好于对照组;未出现黏膜出血等明显不良表现.结论采用低分子肝素钙联合川穹嗪、糖皮质激素治疗 COPD 是可行的和安全的.
목적탐토저분자간소개연합천궁진、당피질격소치료만성조새성폐질병(COPD)적가행성급안전성.방법파2008~2011년수치적200례만성조새성폐질병환자수궤분위량조.대조조:채용저류량지속흡양、항감염、화담급체위인류배담、확장지기관등대증처리.관찰조:재대조조치료적기출상가용저분자간소개、천궁진、당피질격소치료.결과일주후,관찰조환자적해담천증상,우심공능불전,생활질량호전솔호우대조조;혈기분석검사:관찰조환자적동맥혈양분압、혈양포화도개선솔호우대조조;6min 보행시험:관찰조호우대조조;미출현점막출혈등명현불량표현.결론채용저분자간소개연합천궁진、당피질격소치료 COPD 시가행적화안전적.
Objective Discussion on the feasibility and safety of low molecular heparin calcium and ligustrazine for treatment of Chronic obstructive pulmonary diseases. Methods 200 COPD patients received from 2008-2011were randomly divided into two groups. Control group(CG): Rescue therapy of continuous low-flow oxygen inhalation,anti-infective therapy, reducing phlegm and postural drainage were given for this group. Observation group(OG): Low molecular heparin calcium, ligustrazine and glucocorticoid were added to the therapy of this group beyond the treatment for CG. Results After treatment for one week,patients in OG are better than CG in the expectoration or asthma symptoms, right ventricular dysfunction and quality of life improvement. Blood gas analysis results show that improvement for arterial partial pressure of oxygen and oxyhemoglobin saturation is better for OG. It also shows that OG get better performance during six-minute walk test results. No advent of symptoms, such as mucosal bleeding, is observed. Conclusion It is possible and safe for the therapy of COPD using low molecular heparin calcium, ligustrazine and glucocorticoid simultaneously.